Does Trazodone Raise Blood Sugar?

Trazodone does not appear to raise blood sugar. Across the available research, this older antidepressant has shown no meaningful link to hyperglycemia, and a large pharmacovigilance analysis found no association between trazodone use and elevated blood glucose. That makes it something of an outlier among psychiatric medications, many of which carry real metabolic risks. The picture gets more interesting when you look at how trazodone’s signature side effect, drowsiness, may actually loop back to benefit blood sugar regulation through better sleep.

What the Evidence Actually Shows

The most direct evidence comes from a study that analyzed spontaneous adverse-event reports to look for patterns between specific antidepressants and blood sugar disturbances. The researchers grouped antidepressants into clusters based on their pharmacological profiles and checked each cluster for associations with both high and low blood sugar. Trazodone showed no association with hyperglycemia, and it also showed no association with hypoglycemia.¹ That’s a clean bill of health on both sides of the glucose equation, which is not something every antidepressant can claim.

A recent narrative review looking at trazodone’s overall safety profile reinforced this finding, concluding that long-term studies show minimal impact on glucose metabolism.² The review also noted that trazodone is generally weight-neutral or may even cause mild weight loss in some people, which matters because weight gain is one of the main pathways through which psychiatric drugs end up disrupting blood sugar.

An animal study examining trazodone’s effects on blood glucose directly found that trazodone did not change blood glucose concentration on its own.³ That distinction is worth emphasizing: when given alone, without any diabetes medication in the mix, trazodone had no independent effect on blood sugar levels.

How Trazodone Compares to Other Psychiatric Medications

If you’re taking trazodone and worrying about blood sugar, you’re probably aware that certain psychiatric drugs carry metabolic baggage. And that concern is well-founded for some medication classes. A review of metabolic disorders induced by psychotropic drugs found that antipsychotics tend to carry the highest metabolic risk, including weight gain, blood sugar dysregulation, and changes in blood lipids. Antidepressants as a whole carry lower metabolic risk than antipsychotics, though there are differences within the antidepressant family itself.⁴

Among antidepressants, selective serotonin reuptake inhibitors (SSRIs) and tricyclics have both been linked to metabolic disturbances in some individuals. Trazodone doesn’t fit neatly into either of those categories. It’s sometimes called a serotonin antagonist and reuptake inhibitor, and its pharmacological profile is distinct enough that it tends to sidestep some of the metabolic effects seen with other classes. The same pharmacovigilance study that cleared trazodone of blood sugar associations did find links between glucose disturbances and certain other antidepressant clusters, including some SSRIs.¹

This relative metabolic innocence is one reason trazodone sometimes gets a second look from clinicians managing patients who already have diabetes or prediabetes and need treatment for depression or insomnia. When the prescribing choice is between a medication with known metabolic effects and one without, that difference matters.

Weight Neutrality and Why It Matters for Blood Sugar

One of the main ways psychiatric medications end up raising blood sugar is indirect: they increase appetite, cause weight gain, and the added body fat eventually leads to insulin resistance. Mirtazapine is a well-known example. Some atypical antipsychotics like olanzapine are even more notorious for this. Trazodone does not have the appetite-stimulating effect seen with mirtazapine or most antipsychotics.²

Some people even lose a small amount of weight on trazodone. This isn’t dramatic enough to make it a weight-loss drug by any stretch, but it does mean that the indirect pathway from medication to weight gain to insulin resistance to higher blood sugar is largely absent with trazodone. For someone with type 2 diabetes who is already carefully managing body weight to keep blood sugar in range, that’s a meaningful practical advantage over alternatives that might add five or ten pounds over six months.

The Sleep Connection

Here is where the story gets counterintuitive. Trazodone is prescribed far more often for insomnia than for depression, typically at lower doses. And poor sleep is itself a risk factor for impaired glucose regulation. When you don’t sleep well, your body produces more cortisol, becomes more insulin-resistant, and has a harder time processing glucose the next day. Chronic sleep deprivation is strongly linked to higher rates of type 2 diabetes.

So a medication that reliably improves sleep could, at least in theory, improve blood sugar control as a secondary benefit. A small study of patients with diabetic neuropathy tested this idea explicitly. After 12 months of trazodone, patients gained about 40 extra minutes of sleep per night and fell asleep roughly 10 minutes faster. Sleep quality improved in about 70% of patients. On the metabolic side, 68% of the group achieved an HbA1c below 7%, and glucose was in the target range 72% of the time on continuous monitoring. The researchers concluded that improved sleep with trazodone contributed to improved glucose control.⁵

That’s a small, uncontrolled study, so the results deserve caution. It’s hard to separate the effect of better sleep from any direct metabolic effect of the drug, and there was no comparison group taking a different sleep aid. A systematic review that examined whether improving sleep patterns can modify insulin resistance in type 2 diabetes found that pharmacological agents like trazodone enhanced sleep but produced inconsistent metabolic benefits across the studies examined.⁶ The honest read of the evidence is that trazodone reliably helps sleep, and better sleep probably helps blood sugar to some degree, but we can’t yet say with confidence how large that benefit is or whether trazodone specifically outperforms other sleep aids in this regard.

Trazodone and Cortisol

One of trazodone’s lesser-known pharmacological effects is its influence on the body’s stress hormone system. A systematic review of trazodone for insomnia noted that a consistent finding in the literature is that trazodone moderates cortisol suppression through the hypothalamic-pituitary-adrenal (HPA) axis.⁷ This is probably part of why it helps with sleep, since an overactive stress response at night is one of the main drivers of insomnia.

The cortisol angle also connects to blood sugar, because cortisol directly raises blood glucose. When cortisol is chronically elevated, as it is in people under prolonged stress or with disrupted sleep, blood sugar stays higher than it should. By dialing down the cortisol response, trazodone could theoretically help keep blood sugar from spiking during the night and early morning, a time when many people with diabetes see their worst readings. This is plausible biology rather than proven clinical benefit, but it adds to the picture of trazodone as metabolically benign or mildly helpful rather than harmful.

An Important Interaction With Diabetes Medications

While trazodone alone does not appear to affect blood sugar, it can change how diabetes medications behave. An animal study investigating the interaction between trazodone and pioglitazone, a drug used to lower blood sugar in type 2 diabetes, found that trazodone significantly enhanced pioglitazone’s glucose-lowering activity. Both single-dose and multiple-dose experiments in rats and rabbits showed the same pattern: when the two drugs were given together, blood sugar dropped more than when pioglitazone was given alone.³

The mechanism appears to be pharmacokinetic rather than metabolic: trazodone increased the blood levels of pioglitazone, likely by interfering with the enzymes that break it down. More drug in the bloodstream means a stronger glucose-lowering effect. The practical implication is that someone taking both trazodone and pioglitazone could experience lower blood sugar than expected, not because trazodone is lowering glucose itself, but because it’s amplifying the diabetes drug’s effect.

This matters because unexpectedly low blood sugar can be just as dangerous as high blood sugar. If you’re on pioglitazone and your doctor adds trazodone, or vice versa, blood sugar monitoring becomes more important in the weeks after the change. The same caution applies in principle to other diabetes medications that share metabolic pathways with trazodone, though pioglitazone is the one that has been specifically studied.

Why People Worry in the First Place

The concern about trazodone and blood sugar usually comes from two places. First, there’s a general awareness that psychiatric medications can mess with metabolism, and that awareness is justified for certain drug classes. Atypical antipsychotics like olanzapine and clozapine carry well-documented risks of weight gain, insulin resistance, and new-onset diabetes. Some antidepressants, particularly paroxetine among the SSRIs and amitriptyline among the tricyclics, have been linked to weight gain that could indirectly affect blood sugar. People sometimes assume the risk applies equally across all psychiatric medications, but it doesn’t. Trazodone’s pharmacological profile gives it a different metabolic footprint.⁴

Second, people with diabetes are often hypervigilant about anything new entering their medication regimen, and rightly so. But that vigilance sometimes leads to avoiding medications that could actually help. Untreated depression and insomnia both independently worsen blood sugar control. If someone with diabetes avoids trazodone because they assume it will raise their blood sugar, and their sleep and mood suffer as a result, the net effect on their glucose management may be worse than if they had taken the drug.

Trazodone in Older Adults

Trazodone is frequently prescribed to older adults, both for insomnia and for behavioral symptoms associated with dementia. This population tends to be metabolically fragile, with high rates of type 2 diabetes and prediabetes. Research on trazodone in elderly patients with dementia has focused primarily on its effects on agitation, sleep, and depression rather than on metabolic outcomes.⁸ Studies in this population show improvements in irritability, agitation, and depressive symptoms, with the metabolic safety profile generally consistent with what is seen in younger adults.

For older adults already managing multiple medications for blood pressure, cholesterol, and blood sugar, the drug-interaction concern described earlier becomes more relevant. Polypharmacy increases the chance that trazodone will interact with something in the medication lineup, even if the interaction isn’t directly about glucose. Orthostatic hypotension, the drop in blood pressure when standing up that trazodone can cause, is also a bigger concern in older adults and can be confused with or complicate symptoms of low blood sugar. If you’re an older adult starting trazodone, the blood sugar question is less about the drug’s direct metabolic effects and more about how it fits into the full picture of everything else you’re taking.

What Monitoring Looks Like in Practice

Even though the evidence is reassuring, it doesn’t hurt to keep an eye on your numbers when starting any new medication. If you have diabetes and your doctor prescribes trazodone, you don’t need to overhaul your monitoring routine. But checking your fasting glucose a few extra times in the first couple of weeks gives you a personal baseline to compare against. If anything, the more important thing to watch for is unexpectedly low blood sugar, especially if you’re also taking a sulfonylurea or insulin alongside a thiazolidinedione like pioglitazone.

For people without diabetes, trazodone is unlikely to be the thing that pushes your blood sugar into concerning territory. If you’re taking it for insomnia at the typical low dose of 25 to 100 milligrams, the metabolic impact is essentially zero based on current evidence. Higher antidepressant doses in the range of 150 to 300 milligrams have also not shown metabolic red flags, though less data exists at the upper end of the dosing range.

The broader lesson from trazodone’s metabolic profile is that not all psychiatric medications carry the same risks, and the answer to “does this drug affect my blood sugar?” depends entirely on which drug you’re talking about. Lumping all antidepressants or all sleep medications together overstates the risk for some and understates it for others. Trazodone falls firmly on the low-risk end of that spectrum.

1
SpringerOpen. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports
2
PubMed Central. A narrative review on trazodone as a multimodal and multifunctional antidepressant: clinical relevance of formulations, dosing, and pharmacokinetic/pharmacodynamic targets – Section: Safety, tolerability, and practical considerations
3
PubMed Central. Influence of trazodone on the pharmacodynamics and pharmacokinetics of pioglitazone
4
Annales d’Endocrinologie. Metabolic disorders induced by psychotropic drugs
5
Diabetes. Improving Sleep by Trazodone Improves Glucose Control
6
The International Journal of Medical Science and Health Research. Does Improving Sleep Patterns Modify Insulin Resistance In Patients With Type 2 Diabetes? : A Systematic Review
7
Innovations in Clinical Neuroscience. Trazodone for Insomnia: A Systematic Review – Section: Pharmacology of Trazodone
8
PubMed Central. Trazodone in the Management of Major Depression Among Elderly Patients with Dementia: A Narrative Review and Clinical Insights